home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Prime Medicine, Inc. - Common Stock (NQ:PRME)

3.460 +0.090 (+2.67%)

Streaming Delayed Price Updated: 3:11 PM EST, Dec 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Prime Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Prime Medicine Announces Proposed Public Offering of Common Stock

February 14, 2024

From Prime Medicine, Inc.

Via GlobeNewswire

Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 01, 2024

From Prime Medicine, Inc.

Via GlobeNewswire

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

January 25, 2024

From Prime Medicine, Inc.

Via GlobeNewswire

Analyst Ratings for Prime Medicine ↗

October 09, 2023

Via Benzinga

2 gene editing stocks to keep on your 2024 watchlist

January 23, 2024

Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

Via MarketBeat

Morgan Stanley Reports Q4 Results, Joins Boeing, Alcoa And Other Big Stocks Moving Lower On Tuesday ↗

January 16, 2024

U.S. stocks traded lower, with the Dow Jones index falling more than 250 points on Tuesday.

Via Benzinga

Topics Stocks

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

January 05, 2024

From Prime Medicine, Inc.

Via GlobeNewswire

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Prime Medicine, Inc.

Via GlobeNewswire

Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

December 22, 2023

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

Via Benzinga

Better Growth Stock: Archer Aviation or Prime Medicine? ↗

December 19, 2023

Which of these innovation-themed growth stocks is the better buy?

Via The Motley Fool

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years ↗

November 30, 2023

This gene-editing company could sport a best-in-class platform.

Via The Motley Fool

Prime Medicine to Present at Upcoming Investor Conferences

November 08, 2023

From Prime Medicine, Inc.

Via GlobeNewswire

Ryanair Holdings, Prime Medicine And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

November 06, 2023

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 06, 2023

Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge...

Via Benzinga

DISH Network, Goodyear And 3 Stocks To Watch Heading Into Monday ↗

November 06, 2023

With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

November 03, 2023

From Prime Medicine, Inc.

Via GlobeNewswire

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

October 27, 2023

From Prime Medicine, Inc.

Via GlobeNewswire

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

October 24, 2023

From Prime Medicine, Inc.

Via GlobeNewswire

7 Biotech Stocks to Get In Now Before Investors Catch On ↗

October 23, 2023

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

Via InvestorPlace

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

October 17, 2023

From Prime Medicine, Inc.

Via GlobeNewswire

Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst ↗

October 09, 2023

BMO Capital Markets has initiated coverage on Prime Medicine Inc (NASDAQ: PRME), a preclinical-stage company focused on developing therapies based on prime editing.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 9, 2023 ↗

October 09, 2023

Via Benzinga

Prime Medicine to Present at Upcoming Investor Conferences

September 19, 2023

From Prime Medicine, Inc.

Via GlobeNewswire

Prime Medicine to Present at Upcoming Investor Conferences

August 31, 2023

From Prime Medicine, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

October 02, 2023

On Monday, 369 companies set new 52-week lows.

Via Benzinga

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 07, 2023

From Prime Medicine, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Tuesday ↗

September 26, 2023

On Tuesday, 386 stocks made new 52-week lows.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗

September 06, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 ↗

July 31, 2023

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com